AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

This month’s executive moves span a diverse range of organisations – from CDMOs and genomics platforms to diagnostics and ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...